The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.

The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.

The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.

The agency cleared lab-based and point-of-care infectious disease and clinical chemistry tests as well as software for digital pathology.

The analyzer is designed to provide extended differential and rapid C-reactive protein whole blood measurement.

The firm's benchtop TruVerus system can now run a total of 26 FDA-cleared assays in three modalities from a single blood collection tube.

NEW YORK — The US Food and Drug Administration has issued warning letters to four direct-to-consumer health testing companies for selling unauthorized blood collection kits for HIV diagnosis.

The autoimmune diagnostic company expects its new assay to be available by the end of this year or in early 2027.

In addition to pushing cuts off until the beginning of 2027, the bill would update the data collection period used to establish the 2027 lab rates from 2019 to 2025.

The trial is being run by the Global Alzheimer's Platform Foundation in partnership with the UK Dementia Research Institute.

The Danaher subsidiary aims to meet clinician needs for flexibility with a range of test size options for its vast installed base.